Conventional approachEpidural
Natural tissue layers separate the electrode from the target.
Contact us 
Closer to the signal.
Built for precision.
A miniaturized intrathecal spinal cord interface designed to sense and stimulate adjacent to the neural target—opening a more direct, efficient path toward closed-loop neuromodulation.
FuturaLead™Intrathecal interface · tablet shown for scale
A different anatomical approach
A shorter path to the neural target.
Conventional spinal cord stimulation leads sit in the epidural space, separated from the dorsal columns by tissue and fluid. Our lead is designed for the intrathecal space—closer to where the signal begins.
Cerebrolytics approachIntrathecal
Designed to place the interface within the CSF space, adjacent to the cord.
Sense
Capture cleaner evoked compound action potentials closer to the dorsal columns—the signal required for responsive, closed-loop control.
Stimulate
Deliver targeted stimulation from an adjacent anatomical position, with the potential to activate the intended fibers at lower thresholds.
Adapt
Use neural feedback to support automated adjustment instead of relying only on repeated manual programming visits.
The interfaceFuturaLead™Intrathecal sensing + stimulation
Relative scaleTablet shown for reference
Preclinical evidence
The signal changes everything.
In comparative preclinical work, intrathecal positioning produced stronger, more complete neural recordings at lower stimulation thresholds than epidural positioning.
ECAP · illustrative morphology
Comparative preclinical and in-silico findings from the development program. Results are not evidence of clinical safety or efficacy.
Designed for adoption
New interface.
Familiar ecosystem.
FuturaLead is being developed for compatibility with existing implantable pulse generators, with the aim of reducing integration friction for established neuromodulation platforms.
Established access precedent
Intrathecal catheter access has decades of clinical use in pain management.
Closed-loop ready by design
Cleaner neural recordings can support more informative feedback and adaptive programming.
Miniaturization opportunity
Lower energy requirements may enable smaller implants and reduce recharge burden.
Painful diabetic neuropathy
A validated therapeutic category. A more direct interface.
Painful diabetic neuropathy can persist despite medication, disrupting sleep, mobility and quality of life. Spinal cord stimulation already has an FDA-approved precedent for managing chronic, intractable lower-limb pain associated with diabetic neuropathy—validating the clinical category, not FuturaLead.
Cerebrolytics could bring a different technical approach to this established indication: closer-to-target stimulation combined with direct neural-response sensing. The clinical question is whether that proximity can deliver durable pain control with lower energy and more objective, closed-loop adjustment.
Pain, sleep and mobility
Measure relief of refractory lower-limb pain alongside sleep interference and everyday function.
Objective neural feedback
Test whether complete ECAP sensing can guide individualized stimulation instead of programming by symptoms alone.
Lower treatment burden
Evaluate energy use, recharge burden and the stability of response over time.
The intended therapeutic claim would be pain management and functional improvement—not glucose control, reversal of diabetes or proven peripheral nerve regeneration.
Translation pathway
From validated prototype to clinical platform.
The program begins with chronic pain nonresponders and uses that focused indication as a beachhead for a broader neural interface.
01
Complete
Prototype + preclinical foundation
Final lead design, in-silico work, preliminary cadaver evaluation, acute large-animal experiments and subacute performance testing.
02
Now
Regulatory-enabling program
Anchoring and implantation tools, biocompatibility and safety work, sensing validation and expanded intellectual property protection.
03
Next
Clinical translation
IDE pathway, first-in-human evaluation, integration with an established implantable pulse generator and pivotal development planning.
04
Horizon
A broader neural interface
Research paths in neurorehabilitation, motor recovery, autonomic regulation and future spine-computer interfaces.
Beyond pain
One access route.
A wider neurological horizon.
NeurorehabilitationMotor recoveryAutonomic regulationSpine-computer interfaces
Strategic collaboration
The interface is the opportunity.
Cerebrolytics is advancing a differentiated spinal cord interface for strategic partnership, clinical collaboration and platform development.